Max Glanz
YOU?
Author Swipe
View article: Assessing cancer therapeutic efficacy in vivo using [ <sup>2</sup> H <sub>7</sub> ]glucose deuterium metabolic imaging
Assessing cancer therapeutic efficacy in vivo using [ <sup>2</sup> H <sub>7</sub> ]glucose deuterium metabolic imaging Open
Metabolic imaging produces powerful visual assessments of organ function in vivo. Current techniques can be improved by safely increasing metabolic contrast. The gold standard, 2-[ 18 F]fluorodeoxyglucose-positron emission tomography (FDG-…
View article: Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD
Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD Open
Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence is increasing annually and affects over a third of US adults. MASLD can progress to metabolic dysfunction-associated steatohepatitis (MASH), characterized by sever…
View article: P188: Synchronized long-read genome, methylene, epigenome, and transcriptome for a putative small fiber peripheral polyneuropathy research study
P188: Synchronized long-read genome, methylene, epigenome, and transcriptome for a putative small fiber peripheral polyneuropathy research study Open
Rare and inherited diseases (RID), while low in prevalence, collectively impact hundreds of millions of people globally. Some RID are well-characterized, while others are ultra- or hyper-rare, making identification and classification extre…
View article: Detecting altered hepatic lipid oxidation by MRI in an animal model of NAFLD
Detecting altered hepatic lipid oxidation by MRI in an animal model of NAFLD Open
Nonalcoholic fatty liver disease (NAFLD) prevalence is increasing annually and affects over a third of U.S. adults. NAFLD can progress to nonalcoholic steatohepatitis (NASH), characterized by severe inflammation and fibrosis. NASH is predi…